{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307926","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.009164+00:00","generated_at":"2026-06-21T02:37:56.654993+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Mirum Pharmaceuticals director Carol Brosgart resigns, becomes senior advisor; Lon Cardon appointed to board","bullets":["Carol L. Brosgart resigned as director and Nominating Committee member effective Dec 19, 2022; no dispute; becomes senior advisor in science and policy.","Lon Cardon, Ph.D., appointed to board as Class I director, term expiring at 2023 annual meeting, and to Nominating and Corporate Governance Committee.","Cardon receives option for 34,000 shares vesting in 3 equal annual installments, plus annual cash retainer of $40,000 ($4,000 for committee service) prorated for 2022.","Cardon eligible for annual option grant of 17,000 shares starting at 2023 annual meeting, prorated per policy.","Standard indemnification agreement entered; no arrangements with other persons for selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307926","json":"https://secwatch.observer/filing/0001193125-22-307926.json","markdown":"https://secwatch.observer/filing/0001193125-22-307926.md","text":"https://secwatch.observer/filing/0001193125-22-307926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/d436545d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:37:56.654993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13c3392870","claim":"Carol L. Brosgart resigned as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"41ea469bb7","claim":"Lon Cardon was appointed as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522307926/0001193125-22-307926-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}